tradingkey.logo
tradingkey.logo
Search

Vanda Pharmaceuticals Announces U.S. Commercial Availability Of Nereus™ (Tradipitant), The First New Pharmacologic Treatment For People With Motion Sickness In More Than 40 Years

ReutersMay 4, 2026 12:08 PM
facebooktwitterlinkedin
View all comments0

- Vanda Pharmaceuticals Inc VNDA.O:

  • VANDA PHARMACEUTICALS ANNOUNCES U.S. COMMERCIAL AVAILABILITY OF NEREUS™ (TRADIPITANT), THE FIRST NEW PHARMACOLOGIC TREATMENT FOR PEOPLE WITH MOTION SICKNESS IN MORE THAN 40 YEARS

  • VANDA PHARMACEUTICALS INC - NEREUS AVAILABLE AT $85 PER DOSE CASH-PAY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI